Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17436793 | 0.78 | GRN (0.49) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL18546331 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL10363328 | 0.76 | GAA (0.50) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL981523 | 0.76 | MEN1 (0.39) | MAPK14MAPK11GAA | |
| SCHEMBL14300702 | 0.76 | GRN (0.49) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL4133531 | 0.75 | GRN (0.44) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL2243158 | 0.74 | MAPK13 (0.54) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL4146349 | 0.74 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL17436792 | 0.73 | GRN (0.43) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL16279357 | 0.71 | GAA (0.43) | MAPK14MAPK13MAPK12MAPK11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303267-B1 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | CYP1B1, UBE2V1, CYP4B1 | MAPK14 2259/4885MAPK13 2382/4885MAPK12 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.